NCT05887492View on ClinicalTrials.gov

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2026

Conditions
Non Small Cell Lung CancerSolid Tumors, AdultLung CancerLung Adenocarcinoma
Interventions
DRUG

TNG260

CoREST inhibitor, administered orally

DRUG

Pembrolizumab

Pembrolizumab, an anti-PD-1 antibody, administered intravenously

Trial Locations (11)

10016

RECRUITING

New York University Langone Health, New York

11501

RECRUITING

NYU Langone Hematology Oncology Associates-Mineola, Mineola

22031

RECRUITING

NEXT Oncology Virginia, Fairfax

34232

RECRUITING

Florida Cancer Specialists, Sarasota

37203

RECRUITING

Sarah Cannon Tennessee Oncology, Nashville

48202

RECRUITING

Henry Ford Health System, Detroit

49546

RECRUITING

START MidWest, Grand Rapids

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

80218

RECRUITING

SCRI at HealthOne, Denver

90404

RECRUITING

UCLA Hematology/Oncology, Santa Monica

02215

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Tango Therapeutics, Inc.

INDUSTRY